Date: April 19, 2016 – April 22, 2016

Precision for Value will be at the annual AMCP Managed Care & Specialty Pharmacy Meeting in San Francisco which will be held April 19-22 at the Moscone West convention center in San Francisco, California.

If you want to meet some of the industry’s recognized leaders who are helping pharma and life sciences companies demonstrate the value of medical innovations to payers, providers and policy makers – then stop by Precision’s booth #307.

In addition Precision will feature two presentations at the event:

Impact of Value – Designing Innovative Models on Drug Costs

When: Thursday, April 21, 2016, 3:00 pm to 4:15 pm

Who: Precision’s Dana P. Goldman, PhD and Darius Lakdawalla, PhD

Where: Room 2014-2018

Value-based pricing models, also known as pay-for-performance or outcomes-based pricing, present one of the most promising models to improve quality without substantially increasing spending. Recent experience in other sectors of health care demonstrates the promise of such approaches, but also the pitfalls. To date, we have not seen much progress in the pharmaceutical sector. This session will review the benefits and risks of specific novel pricing arrangements and identify the most promising approaches for moving to pay-for-performance.



Update on Safety and Economic Impact of Biosimilars

When: Wednesday, April 20, 2016, 12:45 pm to 2:00 pm

Who: Precision’s Jeremy Shafer, Vice President, Director Specialty Solutions and Alexander S. Grosvenor

Where: Room 2001-2005

Description: Biosimilars represent a significant cost savings opportunity for the United States and European health care systems. This session will compare and contrast the most recent safety and economic data of biosimilars through case studies of select European countries and the early experience in the US. In addition, the faculty will provide a glimpse into the outlook for the United States, including findings from research conducted on U.S. payers regarding their market expectations, perceived barriers, and expected discounts for biosimilars. To learn more visit: